aVLFA0822p Farmakologie II - přednáška

Lékařská fakulta
jaro 2020
Rozsah
2/0/0. 30. 4 kr. Ukončení: zk.
Vyučující
doc. MUDr. Regina Demlová, Ph.D. (přednášející)
doc. PharmDr. Jan Juřica, Ph.D. (přednášející)
Mgr. Petra Amchová, Ph.D. (přednášející)
doc. RNDr. Ladislava Bartošová, Ph.D. (přednášející)
Mgr. Jana Kubátová, Ph.D. (přednášející)
doc. Mgr. MVDr. Leoš Landa, Ph.D. (přednášející)
Mgr. Kristýna Nosková, Ph.D. (přednášející)
MUDr. Jana Nováková, Ph.D. (přednášející)
MUDr. Jana Pistovčáková, Ph.D. (přednášející)
doc. PharmDr. Jana Rudá, Ph.D. (přednášející)
PharmDr. Jitka Rychlíčková, Ph.D. (přednášející)
Mgr. Barbora Říhová, Ph.D. (přednášející)
doc. PharmDr. Ondřej Zendulka, Ph.D. (přednášející)
MUDr. Agnes Adamová (pomocník)
MUDr. Róbert Balog (pomocník)
Renata Bláblová (pomocník)
PharmDr. Eva Klásková (pomocník)
Květoslava Sedlářová (pomocník)
MUDr. Filip Šiška (pomocník)
PharmDr. Katarína Kostolanská (náhr. zkoušející)
Garance
doc. MUDr. Regina Demlová, Ph.D.
Farmakologický ústav – Teoretická pracoviště – Lékařská fakulta
Kontaktní osoba: doc. PharmDr. Ondřej Zendulka, Ph.D.
Dodavatelské pracoviště: Farmakologický ústav – Teoretická pracoviště – Lékařská fakulta
Rozvrh
Út 17:00–18:40 B11/114, kromě Út 14. 4., kromě Út 21. 4., kromě Út 5. 5.
Předpoklady
aVLFA0721p Farmakologie I - přednáška && aVLPF0622p Patol. fyziologie II - před
Omezení zápisu do předmětu
Předmět je nabízen i studentům mimo mateřské obory.
Mateřské obory/plány
Cíle předmětu
The aim of the course is to acquiant the students with drugs from selected pharmacotherapeutic groups.
Výstupy z učení
At the end of the course student should be able choose and prescribe suitable drug for the patient with known indicication. The selection will be made with respect to all factors influencing drug safety and efficacy.
Osnova
  • aVLFA0822p - Pharmacology II lecture

    Spring semester 2020

    17:00-18:40 A11/114

  • 18. 2. 2020
  • 1. DRUGS OF DISEASES WITH CHRONIC PULMONARY OBSTRUCTION, H 1/-ANTIHISTAMINES.
  • Lecture content: Effects of histamine and how to antagonize it. Classification of H1-antihistamines. Pharmacological review of drugs used in the therapy of diseases with chronic pulmonary obstruction.
  • 25. 2. 2020
  • 2. INTRODUCTION TO PSYCHOPHARMACOLOGY, ANTIPSYCHOTICS, ANTIPARKINSONICS
  • Lecture content: History and classification of psychotropic substances. Antipsychotics, antiparkinsonics – basic pharmacological review.
  • 3. 3. 2020
  • 3. ANTIDEPRESSANTS
  • Lecture content: Pharmacological review of antidepressants and their clinical use.
  • 10. 3. 2020
  • 4. ANXIOLYTICS, HYPNOSEDATIVES, ANTICONVULSANTS .
  • Lecture content: Anxiolytics, hypnosedatives, anticonvulsants - basic pharmacological review. The possibilities of modulation of GABAergic neurotransmission.
  • 17. 3. 2020
  • 5. ANTI-INFECTIVES I - ANTIBIOTICS
  • Lecture content: Introduction/principles of ATB therapy, modes of resistance, pharmacological review of single groups of ATBs.
  • 24. 3. 2020
  • ANTI-INFECTIVES II – ANTIMYCOTICS AND ANTIVIRALS
  • Lecture content: Systemic and local antimycotics; antiherpetics; pharmacotherapy of influenza; antiretrovirals; therapy of RSV and viral hepatitis – pharmacological review.
  • 31. 3. 2020 7. PHARMACOLOGY OF GIT – ULCER DISEASE, ANTIEMETICS, ANTIDIARRHEALS AND LAXATIVES
  • Lecture content: Pharmacological review of drugs acting on GIT.
  • 7. 4. 2020
  • 8. CYTOSTATICS AND TARGETED THERAPY IN ONCOLOGY
  • Lecture content: Introduction. Classification of cytostatics according to their mechanisms of action. Mechanisms of resistance to anticancer drugs. Role of single nucleotide polymorphisms (SNPs) and TDM in oncology. Basic pharmacological properties of selected cytostatics. Principles of targeted therapy in oncology. Monoclonal antibodies. Protein kinase inhibitors. Targeted immunotherapy.
  • 14. 4. 2020
  • 9. ANTIANGIAL DRUGS
  • Lecture content: Pharmacological review of drugs used in the treatment of both acute and chronic ischemic heart disease.
  • 21. 4. 2020
  • 10. ANTIHYPERTENSIVES
  • Lecture content: Pharmacological review of antihypertensives with special focus on drugs interfering with RAAS and diuretics. Second-line antihypertensives.
  • 28. 4. 2020
  • 11. DRUGS OF HEART FAILURE, ANTIARRHYTHMICS
  • Lecture content: Review of drugs used in the therapy of acute and chronic heart failure, Pharmacological review of antiarrhythmics.
  • 5. 5. 2020
  • 12. DRUGS INFLUENCING HEMOSTASIS
  • Lecture content: Pharmacological review of anticoagulants, antiplatelets, fibrinolytics, and hemostatics
  • 12. 5. 2020
  • 13. THERAPY OF INTOXICATIONS, SUBSTANCE ADDICTION
  • Lecture content: Review of most common intoxications and their symptomatology. General principles of poisoning management. Specific antidotes in poisoning therapy. Types of addiction, therapy of substance abuse.
  • 19. 5. 2020
  • 14. DRUG-DRUG INTERACTIONS
  • Lecture content: Classification of drug-drug interaction, evaluation of clinical relevance and seriousness oc drug interactions, management of drug interactions, possibilities of drug interactions monitoring, case-reports.
  • 26. 5. 2020
  • 15. PHYTOPHARMACOLOGY AND PHARMACOGNOSY
  • Lecture content: Natural sources of medicines, selected groups of herbal active components, herbal preparations. The most common herbal poisons.
Literatura
    povinná literatura
  • RANG, H. P., James RITTER, R. J. FLOWER a Graeme HENDERSON. Rang & Dale's pharmacology. Eighth edition. [Edinburgh]: Churchill Livingstone, 2016, xv, 760. ISBN 9780702053627. info
    doporučená literatura
  • WHALEN, Karen. Pharmacology. Edited by Richard Finkel - Thomas A. Panavelil. 6th ed. Philadelphia, Pa.: Lippincott Williams & Wilkins, 2015, xi, 664. ISBN 9781451191776. info
    neurčeno
  • Exam question outlines in the IS
  • Study materials in the IS, course aVLFA0822p and aVLFA0822c
Výukové metody
lectures
Metody hodnocení
The final evaluation of the course contains also results of the tests from practicals of both semesters and results of colloquium test.

The final mark is calculated by following method:

Relative weight of the mark from tests: 30 %
Relative weight of the mark from oral exam: 70 %

To calculate mark from the tests the following method will be used:
The summary score from all tests in courses VLFA07212c, VLFA07212p, VLFA08222c, and VLFA08222p is 230 pts. Minimum to pass through the course to the oral exam is 116 pts.
A = 205-230 pts
B = 185-204 pts
C = 155-184 pts
D = 140-154 pts
E = 117-139 pts
F = less than 116 pts

To calculate mark from the oral examthe following method will be used:
Three different questions are chosen by students from three different sets of questions at oral exam. Moreover the student answers additional questions of examinator. Drawn questions from General and Special pharmacology and the additional questions have relative weight of 30 %. The question on essential drugs has realtive weight 10 % in the final mark of the oral exam. When student is evaluated by F for any of these questions the overall rating of oral exam is also F.

In case of success with the ROPOT test, but classification F from the oral part, students enter the oral part next time and for the final mark the score from the last ROPOT attempt is used.
Vyučovací jazyk
Angličtina
Informace učitele

General pharmacology:

1. Pharmacology, sub-branches, origin of drugs, drug names.
2. Types of pharmacotherapy, rules of rational and safe pharmacotherapy. The question of drug misuse.
3. Preclinical and clinical trials, stages.
4. Basic legislation related to drug use, Sources of information on drugs and medicinal products.
5. Solid and gaseous pharmaceutical drug dosage forms - overview and their influence on pharmacokinetics and pharmacodynamics.
6. Semi-solid and liquid pharmaceutical drug dosage forms - overview and their influence on pharmacokinetics and pharmacodynamics.
7. Routes of drug administration – overview, characteristics.
8. Drug absorption, presystemic elimination, drug bioavailability.
9. Drug distribution, volume of distribution, redistribution. General principles of drug movement through the body.
10. Drug elimination, processes of the first and zero order, drug accumulation.
11. Drug biotransformation – stages, examples.
12. Drug excretion (ways of excretion, possibilities of their influence).
13. Therapeutic monitoring of drugs (TDM).
14. Pharmacokinetics of single, repeated and continual drug administration.
15. Modes of drug action
16. Inhibition and induction of enzymes in pharmacokinetics and pharmacodynamics of drugs – examples.
17. Synergism and antagonism in drug effect (pharmacokinetics, pharmacodynamics).
18. Dose – response curves, types of doses, drug anamnesis, patient‘s adherence.
19. Adverse drug reactions (types, categories, examples).
20. Pharmacovigilance, drug safety.
21. Primary resistance of the patient to the treatment. Influence of repeated administration on drug efficacy - examples of tolerance and tachyphylaxis.
22. Factors influencing the drug effect – examples.
23. Pharmacotherapy in elderly, the influence of co-morbidities on drug effect, polypharmacy.
24. Pharmacotherapy in pediatric population, in breastfeeding women. Drugs influencing breast feeding.
25. Pharmacotherapy in pregnancy, drug teratogenicity.
26. Pharmacogenetics, influence of genetic polymorphisms on pharmacokinetics and pharmacodynamics of drugs.
27. Drug interactions - overview, examples.
28. Principles of biological treatment – classification, technology, examples of clinical use.


Special pharmacology:


1. Sympathomimetics - overview of single classes and their indications, examples of drugs
2. Sympatholytics - overview of single classes and their indications, examples of drugs
3. Cholinomimetics
4. Cholinolytics
5. Antispasmodics - GIT + UGT
6. Opioid analgesics
7. NSAIDs, non-opioid analgesics, antimigraine agents
8. Antiuratics, antirheumatics incl. DMARDs
9. General anesthetics
10. Local anesthetics
11. Muscle relaxants
12. Antidiabetics (except insulins)
13. Insulins
14. Sex hormones and hormones of H-P axis
15. Uterotonics and tocolytics
16. Glucocorticoids
17. Immunostimulants + immunosuppressants (except glucocorticoids)
18. Drugs used in osteoporosis, pharmacology of thyroid gland
19. Antiasthmatics, drugs used in COPD
20. Antitussives, mucoactive drugs
21. H1 antihistamines
22. Antipsychotics
23. Drugs of neurogenerative diseases (Parkinson’s disease; dementia)
24. Antidepressants - iMAO+SSRI+NDRI
25. Antidepressants - tricyclic, NASSA, MASSA, SARI, SNRI, NARI, SMS
26. Nootropics, cognitive enhancers
27. Psychotomimetics, drugs used in ADHD
28. Anticonvulsants
29. Hypnosedatives, anxiolytics
30. Principles of antibacterial therapy – overview, modes of action, resistance, MIC, MBC
31. Penicillins, carbapenems
32. Cephalosporines, monobactams
33. Lincosamides, glycopeptides, polymyxins
34. Tetracyclines + related ATBs, amphenicoles
35. Macrolides and related ATBs
36. Aminoglycosides
37. Sulphonamides, nitrofurans and nitroimidazoles
38. Quinolones, antituberculotics
39. Antimycotics
40. Dermatologics – overview of classes, drugs and effects
41. Antivirotics
42. Antiemetic drugs, prokinetics, antivertigo drugs
43. Laxatives, antidiarrhoics, drugs of infectious diarrhoeas
44. Antiulcer agents, hepatoprotectives and drugs influencing the production and excretion of bile
45. Drugs for inflammatory bowel disease
46. Alkylating cytostatics and other drugs aiming on DNA in oncology
47. Antimetabolites + hormonal therapy in oncology
48. Targeted treatment in oncology
49. Biological treatment of autoimmune diseases
50. Hypolipidemics, anti-obesity drugs
51. Antiangial agents
52. Antihypertensives – drugs targeting RAAS
53. Antihypertensives – diuretics and aldosterone antagonists
54. Antihypertensives beta blockers + central antihypertensives
55. Antihypertensives - calcium channel blockers, α1 lytics
56. Antiarrhythmics
57. Drugs used in heart failure
58. Antiplatelet agents
59. Fibrinolytics, antifibrinolytics
60. Anticoagulants
61. Antianemics, hemostatics
62. Drugs causing addiction
63. Drugs used in the treatment of addiction
64. General principles of drug poisoning, specific antidotes and their mechanisms of action
65. Drugs used in erectile dysfunction and BHP
66. Vitamins
67. Antiglaucomatics and cycloplegics


„Essential drugs“

1. adrenalin/noradrenalin
2. dobutamine
3. ephedrine/pseudoephedrine
4. phenylephrine
5. oxymetazoline
6. methyldopa
7. salbutamol
8. doxazosin
9. metoprolol
10. timolol
11. atropine
12. butylscopolamine
13. fenpiverine/pitofenone
14. pilocarpine
15. rivastigmine
16. physostigmine
17. solifenacin
18. paracetamol/ASA
19. ibuprofen/diclofenac
20. indomethacin
21. nimesulide/meloxicam
22. buprenorphine
23. morphine/naloxone
24. sufentanil
25. tramadol
26. metamizole
27. allopurinol
28. sumatriptan
29. desflurane
30. propofol
31. ketamine
32. procaine/lidocaine
33. suxamethonium
34. prilocaine
35. metformin
36. glimepiride
37. sitagliptin
38. insulin lispro
39. insulin glargine
40. ethinylestradiol
41. cyproterone
42. tibolone
43. tamoxifen
44. hexoprenaline
45. oxytocin
46. levonorgestrel
47. dexamethasone
48. prednisone
49. cyclosporine
50. interferons
51. methotrexate
52. ibandronic acid
53. acetylcysteine
54. codeine
55. butamirate
56. ipratropium-bromide
57. bisulepine/cetirizine
58. haloperidol
59. olanzapine
60. aripiprazole
61. levodopa/carbidopa
62. metoclopramide
63. escitalopram
64. amitriptyline
65. mirtazapine
66. lithium
67. methylphenidate
68. piracetam/pyritinol
69. diazepam
70. buspirone
71. gabapentin/pregabalin
72. carbamazepine
73. valproic acid
74. zolpidem
75. midazolam
76. phenoxymethylpenicillin
77. co-amoxicillin
78. piperacillin
79. cefuroxime
80. meropenem
81. vancomycin
82. doxycycline
83. clarithromycin
84. azithromycin
85. gentamicin
86. cotrimoxazole
87. ciprofloxacin
88. rifampicin
89. terbinafine
90. caspofungin
91. amphotericin B
92. fluconazole
93. acyclovir
94. zidovudine
95. isotretinoin
96. salicylic acid
97. ondansetron
98. moxastine
99. pantoprazole
100. famotidine
101. lactulose
102. aprepitant
103. loperamide
104. betahistine
105. cinnarizine
106. cyclophosphamide
107. methotrexate
108. 5-fluorouracil
109. paclitaxel
110. doxorubicin
111. cisplatin
112. trastuzumab
113. imatinib
114. interferon alfa
115. nivolumab
116. atorvastatin
117. fenofibrate
118. ezetimibe
119. isosorbid dinitrate/nitroglycerin
120. hydrochlorothiazide/indapamide
121. furosemide
122. spironolactone
123. amlodipine
124. perindopril
125. telmisartan
126. digoxin
127. amiodarone
128. verapamil
129. levosimendan
130. warfarin
131. enoxaparin
132. clopidogrel
133. dabigatran
134. rivaroxaban
135. alteplase
136. methadone
137. buprenorphine
138. nalmefene
139. naltrexone
140. finasteride
141. sildenafil
Další komentáře
Studijní materiály
Předmět je vyučován každoročně.
Nachází se v prerekvizitách jiných předmětů

Zobrazit další předměty

Předmět je zařazen také v obdobích jaro 2018, jaro 2019, jaro 2021, jaro 2022, jaro 2023, jaro 2024, jaro 2025.